Related Experiment Video
Updated: Mar 3, 2026
08:54
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
21.2K
Antifungal Pharmacokinetics/Pharmacodynamics
Yusuke Yagi1,2, Yukihiro Hamada1
1Department of Pharmacy, Kochi Medical School Hospital.
Medical Mycology Journal
|March 1, 2026
Summary
Optimizing antifungal therapy using pharmacokinetics/pharmacodynamics (PK/PD) is key for invasive fungal infections. Bridging research and practice requires addressing knowledge gaps and variability for better patient outcomes.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Pharmacy
Background:
- Optimizing antifungal therapy with pharmacokinetics/pharmacodynamics (PK/PK) principles is crucial for invasive fungal infections.
- Clinical application faces significant challenges, including knowledge gaps and inter-patient variability.
Purpose of the Study:
- To provide a comprehensive overview of PK/PD in antifungal therapy.
- To bridge basic research and clinical practice by analyzing challenges and future directions.
Main Methods:
- Review of fundamental PK/PD concepts and major antifungal drug classes.
- Analysis of preclinical evidence defining key PK/PD indices.
- Critical evaluation of challenges hindering clinical translation.
Main Results:
- Identified key PK/PD indices: concentration-to-minimum inhibitory concentration ratio, 24-h area under the curve-to-minimum inhibitory concentration ratio, and time above minimum inhibitory concentration.
- Highlighted challenges: knowledge gaps (especially for filamentous fungi), pharmacokinetic variability, TDM limitations, narrow therapeutic windows, and antifungal resistance.
- Discussed current strategies like antifungal stewardship.
Conclusions:
- Effective application of PK/PD principles is vital for personalized antifungal therapies.
- Future directions include prioritizing research, improving TDM, developing novel agents, and enhancing research-clinical collaboration.
Keywords:
antifungal resistanceantifungal stewardshipantifungal therapypharmacokinetics/pharmacodynamicstherapeutic drug monitoringMore Related Videos
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
55
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
55
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
68
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
68
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
383
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
383
01:25Pharmacokinetics: Drug–Drug Interactions
545
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
545
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
48
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
48
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
340
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
340